Oral contraception rights sold by Galen for €37m
Pharmaceutical companies Galen and Barr this morning announced that they have closed two out of the three parts of their outstanding deal originally announced last September, which was under FTC review.
Firstly, Galen has sold exclusive rights in the US and Canada for its Loestrin and Loestrin FE oral contraceptive products to Barr Pharmaceuticals for $45m (€37.1m).